Impact of Mifepristone, a Glucocorticoid/Progesterone Antagonist, on HDL Cholesterol, HDL Particle Concentration, and HDL Function

CONTEXT: Mifepristone is a glucocorticoid and progestin antagonist under investigation for the treatment of Cushing's syndrome. Mifepristone decreases high-density lipoprotein (HDL) cholesterol (HDL-C) levels in treated patients, but the clinical significance of this is unclear because recent s...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Page, Stephanie T., Krauss, Ronald M., Gross, Coleman, Ishida, Brian, Heinecke, Jay W., Tang, Chongren, Amory, John K., Schaefer, Peter M., Cox, Cheryl J., Kane, John, Purnell, Jonathan Q., Weinstein, Richard L., Vaisar, Tomáš
Format: Artigo
Langue:Inglês
Publié: Endocrine Society 2012
Sujets:
Endocrine Care
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3339893/
https://ncbi.nlm.nih.gov/pubmed/22399518
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2011-2813
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires